J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0091270007302953v1
47/9/1129    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Extramiana, F.
Right arrow Articles by Maison-Blanche, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Extramiana, F.
Right arrow Articles by Maison-Blanche, P.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

CLINICAL STUDIES

Contrasting Time- and Rate-Based Approaches for the Assessment of Drug-Induced QT Changes

Fabrice Extramiana, MD, PhD, Fabio Badilini, PhD, Nenad Sarapa, MD, Antoine Leenhardt, MD and Pierre Maison-Blanche, MD

From Lariboisière University Hospital—APHP—Paris 7 University, France (Dr Extramiana, Dr Leenhardt, Dr Maison-Blanche); AMPS LLC, New York (Dr Badilini); and Daiichi Sankyo Pharma Development, Edison, New Jersey (Dr Sarapa).

The authors aim to highlight the pitfalls of different validated methods used for the assessment of drugs' effect on QT duration. Digital 12-lead Holter electrocardiograms were recorded at baseline and after a single dose of sotalol in 39 healthy subjects (age = 27.4 ± 8.0 years). Using both time- and rate-based approaches, the authors obtained averaged QRS-T complexes every minute ("time bins") and at different RR intervals ("rate bins"). Time bins were corrected for heart rate using a subject-specific approach. The individual {alpha} coefficients increased from placebo (0.309 ± 0.052) to sotalol (0.454 ± 0.136), P < .0001. When the placebo individual {alpha} coefficients were applied to correct the QT interval on sotalol, the changes were >5 ms smaller than those obtained using the ON drug {alpha} coefficients. The "rate"-averaging process leads to a complete loss of the time course of drug effect. In conclusion, the individual correction formula calculated from the placebo condition cannot always be used for QT correction on the drug.

Key Words: QT interval • sotalol • Holter ECG

Address for correspondence: Fabrice Extramiana, MD, PhD, Cardiology Department—Lariboisière University Hospital, 2 rue Ambroise Parè—75010, Paris, France; e-mail: Fabrice.extramiana{at}lrb.aphp.fr.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology